The Treatment of Glabellar Frown Lines
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02096081. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to show that two FDA-approved botulinum toxin drugs called Xeomin® and Botox® can reduce the severity of vertical lines (wrinkles) that appear between the eyebrows (glabellar frown lines).
Study identification
- NCT ID
- NCT02096081
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 250 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 50 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2014 (Type not available)
- Primary completion
- Aug 2014 (Actual)
- Completion
- Nov 2014 (Actual)
- Last update posted
- Oct 19, 2017
2014
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Merz Investigative Site #001099 | Los Angeles | California | 90069 | — |
| Merz Investigative Site #001300 | Sacramento | California | 95819 | — |
| Merz Investigative Site #001299 | Santa Monica | California | 90404 | — |
| Merz Investigative Site #001298 | Washington D.C. | District of Columbia | 20005 | — |
| Merz Investigative Site #001170 | Washington D.C. | District of Columbia | 20037 | — |
| Merz Investigative Site #001101 | Coral Gables | Florida | 33146 | — |
| Merz Investigative Site #001105 | Metairie | Louisiana | 70006 | — |
| Merz Investigative Site #001098 | Chestnut Hill | Massachusetts | 02467 | — |
| Merz Investigative Site #001297 | New York | New York | 10065 | — |
| Merz Investigative Site #001097 | Nashville | Tennessee | 37215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02096081, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 19, 2017 · Synced Nov 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.